They say, “You can’t make a silk purse out of a sow’s ear,” and nowhere does this ring truer than in artificial intelligence (AI). As AI shifts the way we do biomedical research from discovering new drugs to tailoring treatments, it’s becoming clear that not all data is created equal. While the old mantra “bigger is better” may have worked for data hoarders of the past, modern AI reminds us that it’s not how much data you have, but how good the data is, that makes all the difference.
Source Url
Author: elucidata .io
Website: https://www.elucidata.io/ Website: https://www.elucidata.io/ Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly’s powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly’s technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data. Address: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Phone No: 9716140329 Contact Email: info@elucidata.io
